Cargando…
The promoter and the enhancer region of the KLK 3 (prostate specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines
KLK3 or prostate specific antigen (PSA) is a serine protease, which is an established tumour marker of prostatic adenocarcinoma. PSA is now used widely for the diagnosis and monitoring of patients with prostate cancer. Recent studies have demonstrated that about 70% of breast cancers produce PSA. In...
Autores principales: | Majumdar, S, Diamandis, E P |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362704/ https://www.ncbi.nlm.nih.gov/pubmed/10188912 http://dx.doi.org/10.1038/sj.bjc.6690254 |
Ejemplares similares
-
Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumour suppressor gene in normal and malignant testicular tissue
por: Luo, L-Y, et al.
Publicado: (2001) -
Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination
por: Yu, H, et al.
Publicado: (1999) -
Mutations in the prostate specific antigen (PSA/KLK3) correlate with male infertility
por: Gupta, Nishi, et al.
Publicado: (2017) -
Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer
por: Foekens, J A, et al.
Publicado: (1999) -
Frequent somatic loss of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers and vice
versa
por: Staff, S, et al.
Publicado: (2001)